Se afișează postările cu eticheta Reduce. Afișați toate postările
Se afișează postările cu eticheta Reduce. Afișați toate postările

marți, 13 decembrie 2011

Private Rooms In Hospitals Does Not Reduce The Incidence Of Gastroenteritis

Main Category: GastroIntestinal / Gastroenterology
Article Date: 13 Dec 2011 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
To offer patients single rooms in hospitals is not enough to prevent gastroenteritis. That is shown in a master thesis at Nordic School of Public Health NHV.

"There must be more preventive measures, where single rooms can be one, to prevent the spreading of infectious diarrhea, says Anita Wang Børseth, Master of Public Health.

The hygiene nurse Anita Wang Børseth master's study is titled Private rooms, an infection and disease prevention in hospitals? The purpose was to see if single rooms to reduce infection. It is mapping the incidence of the infectious intestinal disease Clostrium difficile in hospitalized patients in four Norwegian hospitals between 2001-2010.

The analysis included to look into if the moving of patients from an old hospital building with a few single rooms, to a new hospital building with only single rooms, was reducing the incidence Clostrium difficile, which can cause diarrhea. The proportion of single rooms has increased during the study period, but this master theisis has not shown an infection preventive effect according to the occurrence of Clostrium difficile. Although no correlation between single rooms and the spread of infection among patients could not be detected.

"But it can be possible that single room is increasing the risk for infection among the health professionals, says Anita Wang Børseth.

There was great disparity in incidence between the four major Norwegian hospitals that participated in this study. The risk of infection appears to be higher in the old hospital, although this could not be detected with statistical significance.

"The conclusion is that there must be more preventive measures, where single rooms can be one measure to prevent the spread of infectious diarrhea says Anita Wang Børseth.

Article adapted by Medical News Today from original press release. Source: Nordic School of Public Health
Visit our gastrointestinal / gastroenterology section for the latest news on this subject. Nordic School of Public Health Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Nordic School of Public Health. "Private Rooms In Hospitals Does Not Reduce The Incidence Of Gastroenteritis." Medical News Today. MediLexicon, Intl., 13 Dec. 2011. Web.
13 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

luni, 12 decembrie 2011

PSA Testing, Combined With Other Relevant Patient Data Can Reduce Unnecessary Prostate Biopsies

Editor's Choice
Main Category: Prostate / Prostate Cancer
Also Included In: Preventive Medicine
Article Date: 12 Dec 2011 - 7:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
A study published online by the journal Cancer reveals that up to one-quarter of men could avoid biopsies and their associated risks with prostate cancer screening that combines an adjusted blood test with other factors including, the patient's family history, overall weight as well as the size of the gland.

According to the team led by Martin G. Sanda, MD, Director of the Prostate Center at Beth Israel Deaconess Medical Center and Professor of Urology at Harvard Medical School, other factors such as prostate size should be taken into consideration when determining which patient should have a biopsy, instead of using "one-size-fits-all" levels of PSA.

Other factors, such as prostate size, can significantly improve the ability of PSA testing to detect aggressive prostate cancers for which treatment is appropriate, while avoiding identification of indolent cancers that do not require treatment.

A second investigation published online in the journal Urologic Oncology, also led by Sanda, reveals that another way to determine if a biopsy is needed is testing for the presence of absence of genes commonly found in the urine of men in conjunction with a PSA test.

The novel suggested methods follow the United States Preventative Services Task Force expert panel conclusion that the present PSA-based prostate cancer screening causes harm through treatment or additional invasive testing, such as biopsies, and saves few or no lives.

Sanda explains:

"That's because prostate cancers can vary in aggressiveness and more men die of other causes aside from that cancer, and because the PSA test alone can not determine how dangerous any particular cancer may be. The US Preventative Services Task Force threw the baby out with the bathwater by their blanket recommendation against prostate cancer screening."

Sanda notes that, instead, PSA screening can be improved to identify only aggressive cancer for which treatment is indicated by adjusting PSA results for other considerations, such as size of prostate, obesity, and family history.

According to results from the multi-center study PSAD levels of less than 0.1 - in comparison to the unadjusted level of between 2.5 and 4 - can be a significant indicator of a potential cancer. Physicians determine the density by a using a digital rectal exam, allowing them to consider other factors like benign prostatic hyperplasia, an enlargement of the gland that affects all men as they age.

The researchers discovered that combining PSAD with the digital exam, an examination of the patient's family history and a body mass index of 25 or less, would avoid biopsy in around one-quarter of biopsy-eligible men.

The researchers state:

"Urological practice, patient outcome and cost-effectiveness of health care would each benefit from new targeted strategies, such as nomograms (a predictive tool) that improve prediction of aggressive cancers, to enable selective identification of candidate for prostate biopsy that would improve the yield of clinically significant, histologically aggressive cancers warranting subsequent definitive treatment."

In an additional multi-center investigation published in Urologic Oncology, investigators explain that a test taken after a digital rectal exam that looks for two specific genetic biomarkers (TMPRSS2:ERG and PCA3), could prevent biopsies in men whose PSA reading ranges between 2-10 and who poses both genes. This could potentially stop one-third of men undergoing unnecessary biopsies.

Sanda, explains:

"Urine testing for prostate cancer is
in its infancy".

Further research is currently underway thanks to a $3.1 million grant from the National Institutes of Health. The study is assessing novel blood and urine test for prostate cancer in over 2,400 men over the next 5 years with the aim of resolving over-diagnosis and over-treatment.

One of the main focuses of proposed study involves a community outreach effort led by BIDMC primary care physician J. Jacques Carter, MD, MPH, Medical Director of the Dana Farber Cancer Institute Prostate Cancer Screening and Education Program and an Assistant Professor of Medicine at Harvard Medical School. A vital component of this investigation will be African-American men, who seem to develop prostate cancer more prevalently, and who have a higher risk of dying from prostate cancer.

Written by: Petra Rattue

Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today

Visit our prostate / prostate cancer section for the latest news on this subject. Beth Israel Deaconess Medical Center Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Petra Rattue. "PSA Testing, Combined With Other Relevant Patient Data Can Reduce Unnecessary Prostate Biopsies." Medical News Today. MediLexicon, Intl., 12 Dec. 2011. Web.
12 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Blood Pressure Medicines Reduce Stroke Risk In People With Prehypertension

Main Category: Hypertension
Also Included In: Stroke
Article Date: 12 Dec 2011 - 0:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
People with prehypertension had a lower risk of stroke when they took blood pressure-lowering medicines, according to research reported in Stroke: Journal of the American Heart Association.

Prehypertension, which affects more than 50 million adults in the United States, is blood pressure ranging between 120/80 mm Hg and 139/89 mm Hg. Hypertension is 140/90 mm Hg or higher.

"Our study pertains to people with pre-hypertensive blood pressure levels and shows that the excess risk of stroke associated with these high-normal readings (top number 120-140) can be altered by taking blood pressure pills," said Ilke Sipahi, M.D., lead author of the study and associate director of Heart Failure and Transplantation at the Harrington-McLaughlin Heart and Vascular Institute in Cleveland, Ohio.

In a meta-analysis of 16 studies, researchers examined data that compared anti-hypertensive drugs against placebo in 70,664 people with average baseline blood pressure levels within the pre-hypertensive range. The researchers found: Patients taking blood pressure-lowering medicines had a 22 percent lower risk of stroke compared to those taking a placebo. This effect was observed across all classes of anti-hypertensive drugs studied. No significant reduction in the risk of heart attack occurred, but there was a trend toward lower cardiovascular death in patients taking blood pressure medications compared to those on placebo. To prevent one stroke in the study population, 169 people had to be treated with a blood pressure-lowering medication for an average 4.3 years. American Heart Association treatment guidelines call for lifestyle changes, not medications, to reduce blood pressure in people with prehypertension. Those lifestyle changes include weight loss, physical activity, a diet rich in fruit and vegetables and low in salt and fat, and keeping alcohol consumption moderate (no more than two drinks per day for men and no more than one drink per day for women).

"We do not think that giving blood pressure medicine instead of implementing the lifestyle changes is the way to go," Sipahi said. "However, the clear-cut reduction in the risk of stroke with blood pressure pills is important and may be complementary to lifestyle changes."

The cost of long-term therapy and the risks associated with blood pressure medicines need to be discussed extensively within the medical community before undertaking guideline changes, Sipahi said.

Co-authors are: Aparna Swaminathan, fourth-year medical student; Viswanath Natesan, M.D.; Sara M. Debanne, Ph.D.; Daniel I. Simon, M.D.; and James C. Fang, M.D. Author disclosures are on the manuscript.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our hypertension section for the latest news on this subject. Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.

American Heart Association

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

American Heart Association. "Blood Pressure Medicines Reduce Stroke Risk In People With Prehypertension." Medical News Today. MediLexicon, Intl., 12 Dec. 2011. Web.
12 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

joi, 8 decembrie 2011

Medical Marijuana Could Help Patients Reduce Pain With Opiates

Main Category: Pain / Anesthetics
Also Included In: Alcohol / Addiction / Illegal Drugs
Article Date: 08 Dec 2011 - 1:00 PST

email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
A UCSF study suggests patients with chronic pain may experience greater relief if their doctors add cannabinoids - the main ingredient in cannabis or medical marijuana - to an opiates-only treatment. The findings, from a small-scale study, also suggest that a combined therapy could result in reduced opiate dosages.

More than 76 million Americans suffer from chronic pain - more people than diabetes, heart disease and cancer combined, according to the National Centers for Health Statistics.

"Pain is a big problem in America and chronic pain is a reason many people utilize the health care system," said the paper's lead author, Donald Abrams, MD, professor of clinical medicine at UCSF and chief of the Hematology-Oncology Division at San Francisco General Hospital and Trauma Center (SFGH). "And chronic pain is, unfortunately, one of the problems we're least capable of managing effectively."

In a paper published this month in Clinical Pharmacology & Therapeutics, researchers examined the interaction between cannabinoids and opiates in the first human study of its kind. They found the combination of the two components reduced pain more than using opiates alone, similar to results previously found in animal studies.

Researchers studied chronic pain patients who were being treated with long-acting morphine or long-acting oxycodone. Their treatment was supplemented with controlled amounts of cannabinoids, inhaled through a vaporizer. The original focus was on whether the opiates' effectiveness increased, not on whether the cannabinoids helped reduce pain.

"The goal of the study really was to determine if inhalation of cannabis changed the level of the opiates in the bloodstream," Abrams said. "The way drugs interact, adding cannabis to the chronic dose of opiates could be expected either to increase the plasma level of the opiates or to decrease the plasma level of the opiates or to have no effect. And while we were doing that, we also asked the patients what happened to their pain."

Abrams and his colleagues studied 21 chronic pain patients in the inpatient Clinical and Transitional Science Institute's Clinical Research Center at SFGH: 10 on sustained-release morphine and 11 on oxycodone. After obtaining opiate levels from patients at the start of the study, researchers exposed them to vaporized cannabis for four consecutive days. On the fifth day, they looked again at the level of opiate in the bloodstream. Because the level of morphine was slightly lower in the patients, and the level of oxycodone was virtually unchanged, "one would expect they would have less relief of pain and what we found that was interesting was that instead of having less pain relief, patients had more pain relief," Abrams said. "So that was a little surprising."

The morphine group came in with a pain score of about 35, and on the fifth day, it decreased to 24 - a 33 percent reduction. The oxycodone group came in with an average pain score of about 44, and it reduced to 34 - a drop of 20 percent. Overall, patients showed a significant decrease in their pain.

"This preliminary study seems to imply that people may be able to get away perhaps taking lower doses of the opiates for longer periods of time if taken in conjunction with cannabis," Abrams said.

Opiates are very strong powerful pain medicines that can be highly addictive. They also can be deadly since opiates sometimes suppress the respiratory system.

As a cancer doctor, Abrams was motivated to find safe and effective treatments for chronic pain. Patients in the cannabis-opiates study experienced no major side effects such as nausea, vomiting or loss of appetite.

"What we need to do now is look at pain as the primary endpoint of a larger trial," he said. "Particularly I would be interested in looking at the effect of different strains of cannabis."

For instance, Delta 9 THC is the main psychoactive component of cannabis but cannabis contains about 70 other similar compounds with different effects. One of those is cannabidiol, or CBD. It appears to be very effective against pain and inflammation without creating the "high" created by THC.

"I think it would be interesting to do a larger study comparing high THC versus high CBD cannabis strains in association with opiates in patients with chronic pain and perhaps even having a placebo as a control," Abrams said. "That would be the next step."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our pain / anesthetics section for the latest news on this subject. Abrams is the lead author of the paper; co-authors are Paul Couey, BA, and Mary Ellen Kelly, MPH, of the UCSF Division of Hematology-Oncology at SFGH; Starley Shade, PhD, of the UCSF Center for AIDS Prevention Studies; and Neal Benowitz, MD, of the UCSF Division of Clinical Pharmacology and Experimental Therapeutics.
The study was supported by funds from the National Institutes on Drug Abuse (NIDA), a subsidiary of the National Institutes of Health (NIH).
University of California - San Francisco Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of California - San Francisco. "Medical Marijuana Could Help Patients Reduce Pain With Opiates." Medical News Today. MediLexicon, Intl., 8 Dec. 2011. Web.
8 Dec. 2011. APA

Please note: If no author information is provided, the source is cited instead.


Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here